Esperion Therapeutics, Inc.

https://esperion.com

Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company headquartered in Ann Arbor, Michigan. The company is dedicated to discovering, developing, and commercializing innovative oral therapies aimed at reducing elevated levels of low-density lipoprotein cholesterol (LDL-C) and mitigating cardiovascular risk. Its mission is to bring new medicines to market that address unmet needs of patients and healthcare professionals in cardiovascular disease management.

Esperion's primary marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets. These are oral, once-daily, non-statin medicines approved for the treatment of primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD), in adults who require additional LDL-C lowering. The company also markets these products in Europe under the brand names NILEMDO and NUSTENDI, respectively.

Sheldon Koenig serves as the President and Chief Executive Officer of Esperion Therapeutics. In a significant recent development, Esperion announced on May 1, 2026, that it has entered into a definitive agreement to be acquired by ARCHIMED, a healthcare investment firm. The transaction, valued at up to $1.1 billion, will provide shareholders with $3.16 per share in cash plus contingent milestone payments. This acquisition is expected to close in the third quarter of 2026, after which Esperion will become a privately held company and its common stock will no longer be listed on Nasdaq. Additionally, on April 2, 2026, Esperion completed the acquisition of Corstasis Therapeutics, adding Enbumyst™ (bumetanide nasal spray) to its cardiovascular portfolio.

Latest updates

Esperion Acquired by ARCHIMED in $1.1 Billion Deal

Event summary

  • Esperion Therapeutics is being acquired by ARCHIMED for up to $1.1 billion in total equity value.
  • Esperion shareholders will receive $3.16 per share in cash and potential contingent milestone payments of up to $100 million.
  • The deal represents a 58% premium to Esperion’s closing share price on April 30, 2026.
  • Following the acquisition, Esperion will become a privately held company and delist from Nasdaq.
  • The transaction is expected to close in the third quarter of 2026, subject to regulatory approvals and shareholder vote.

The big picture

The acquisition of Esperion by ARCHIMED, a €9 billion investment firm, underscores the continued appetite for specialized biopharma assets, particularly those with established commercial products in the cardiometabolic space. This deal highlights a trend of private equity firms seeking to consolidate and optimize biopharmaceutical companies, leveraging their operational expertise to drive growth and profitability. The contingent milestone structure suggests ARCHIMED sees significant upside potential but also recognizes the inherent risks associated with commercializing pharmaceutical products.

What we're watching

Milestone Risk
The contingent milestone payments, tied to sales of bempedoic acid and bumetanide, represent a significant portion of the total deal value and their achievement is far from guaranteed, introducing execution risk for ARCHIMED.
Integration Challenges
ARCHIMED’s operational expertise will be tested as it integrates Esperion, particularly given Esperion’s existing commercial infrastructure and pipeline, and the potential for cultural clashes.
Pipeline Focus
The acquisition may signal a shift in Esperion's strategic priorities, with ARCHIMED potentially narrowing the focus to core cardiometabolic products and deprioritizing the broader pipeline, including treatments for Primary Sclerosing Cholangitis and renal diseases.

Esperion to Detail Q1 2026 Results Amidst Cardiometabolic Market Scrutiny

Event summary

  • Esperion Therapeutics will release its first quarter 2026 financial results on May 7, 2026, before market open.
  • A webcast and replay will be available on the company's investor relations website.
  • Esperion markets two oral, once-daily, non-statin therapies for LDL-C management and cardiovascular risk.
  • The company has a commercial infrastructure in the U.S. and global approvals in over 40 countries.
  • Esperion is pursuing partnerships for U.S. market access through various agreements.

The big picture

Esperion's positioning as a partner-of-choice for global innovators highlights a strategic shift towards leveraging its U.S. commercial infrastructure. This model, while potentially lucrative, hinges on securing attractive in-licensing or co-promotion deals in a competitive biopharmaceutical landscape. The company’s focus on ACLY biology represents a niche expertise, but its long-term success depends on translating that expertise into a robust pipeline of commercially viable therapies.

What we're watching

Market Dynamics
The performance of Esperion’s existing therapies will be a key indicator of the broader market’s acceptance of non-statin treatments, given increasing competition and evolving clinical guidelines.
Pipeline Progress
The company’s advancement of treatments for Primary Sclerosing Cholangitis and renal diseases will be scrutinized, as diversification beyond cardiometabolic therapies is crucial for long-term growth.
Partnership Strategy
The success of Esperion’s partnership model for U.S. market access will determine its ability to expand its product portfolio and revenue streams without significant internal investment.

Esperion Acquires Corstasis, Bolsters Cardiovascular Portfolio with Nasal Diuretic

Event summary

  • Esperion Therapeutics completed its acquisition of privately-held Corstasis Therapeutics on April 2, 2026.
  • The acquisition brings Enbumyst, the first FDA-approved nasal spray loop diuretic, into Esperion’s cardiovascular franchise.
  • Enbumyst received FDA approval in September 2025 for edema treatment associated with congestive heart failure, hepatic, and renal disease.
  • Esperion intends to leverage its existing cardiovascular commercial infrastructure to drive Enbumyst adoption.

The big picture

Esperion’s acquisition of Corstasis represents a strategic move to expand its presence in the cardiometabolic space, a market facing increasing global burden. The acquisition of Enbumyst, a novel nasal spray diuretic, provides a differentiated offering within the outpatient setting, but its success hinges on effective commercialization and payer acceptance. This acquisition underscores the ongoing trend of biopharma companies seeking to bolster their portfolios with innovative, patient-centric therapies.

What we're watching

Commercial Execution
Esperion's ability to integrate Corstasis's commercial operations and effectively leverage its existing infrastructure will be critical to Enbumyst's success and will dictate the pace of revenue generation.
Payer Adoption
Given Enbumyst's novel delivery method, securing favorable reimbursement and formulary placement from payers will be essential for broad patient access and market penetration.
Competitive Landscape
The emergence of a category-first product may attract competitors seeking to develop alternative, convenient diuretic therapies, potentially eroding Esperion's market share over time.

Esperion Data Shows Stroke Risk Reduction with Bempedoic Acid

Event summary

  • Esperion presented post-hoc analyses from the CLEAR Outcomes trial at ACC.26.
  • The data indicated a 22% reduction in ischemic stroke risk with bempedoic acid compared to placebo.
  • Bempedoic acid demonstrated similar cardiovascular benefit in patients with autoimmune/inflammatory diseases as in those without.
  • The trial included 13,970 participants, with approximately 10% having autoimmune/inflammatory diseases.

The big picture

Esperion's CLEAR Outcomes data reinforces the value of bempedoic acid in a niche market – statin-intolerant patients at high cardiovascular risk. The consistent benefit observed across diverse populations, including those with autoimmune diseases, broadens the potential patient pool and strengthens the drug's clinical profile. However, Esperion's success hinges on continued market adoption and navigating potential regulatory hurdles related to safety concerns.

What we're watching

Adoption Rate
The speed at which physicians incorporate bempedoic acid into treatment plans, particularly given the statin intolerance patient population, will determine Esperion's revenue trajectory.
Regulatory Scrutiny
Continued monitoring of tendon rupture risk and hyperuricemia will be crucial, as any significant adverse event findings could impact labeling and market access.
Competitive Landscape
The emergence of competing therapies targeting similar patient populations could erode Esperion’s market share and pricing power.

Esperion Data to Highlight Statin Alternatives in ACC Presentation

Event summary

  • Esperion will present two analyses from the CLEAR Outcomes trial at the American College of Cardiology (ACC.26) conference, March 28-30, 2026.
  • One analysis focuses on the incidence of stroke in statin-intolerant patients, while the other examines cardiovascular outcomes in patients with autoimmune or inflammatory diseases.
  • Carolina Pires Zingano and Bernardo Frison Spiazzi of Cleveland Clinic are listed as presenters for the respective analyses.
  • The presentations aim to provide further insights into the efficacy of bempedoic acid as an alternative to statins.

The big picture

Esperion is attempting to carve out a niche in the crowded statin market by targeting patients who are intolerant or unresponsive to traditional therapies. The CLEAR Outcomes trial data is crucial for validating this strategy and demonstrating the clinical utility of bempedoic acid. The company's broader ambition to leverage ACLY biology for a diversified pipeline adds another layer of complexity and potential for future growth, but hinges on the success of its current cardiovascular offerings.

What we're watching

Market Adoption
The reception of these analyses by leading cardiologists at ACC.26 will likely influence physician adoption of bempedoic acid and its position relative to existing statin alternatives.
Clinical Validation
Further scrutiny of the CLEAR Outcomes data may reveal nuances in patient populations where bempedoic acid demonstrates the most significant benefit, potentially narrowing or broadening its target market.
Pipeline Expansion
Esperion's stated focus on ACLY biology suggests these cardiovascular therapies could serve as a platform for future product development, and the success of bempedoic acid will be a key determinant of that strategy.

Esperion's Bempedoic Acid Gains Top-Tier Guideline Endorsement

Event summary

  • Esperion’s bempedoic acid (NEXLETOL/NEXLIZET) received multiple Class 1 recommendations in the 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia.
  • The guidelines endorse bempedoic acid for patients with statin intolerance, and for high-risk primary and secondary prevention patients with severe hypercholesterolemia.
  • Bempedoic acid is now positioned equally with PCSK9 mAbs and ezetimibe after statins for high-risk primary prevention patients.
  • The guidelines reintroduce LDL-C targets and emphasize early combination lipid-lowering therapy, reflecting a ‘lower for longer’ approach.

The big picture

The ACC/AHA guideline endorsement validates a shift towards more aggressive and earlier lipid-lowering interventions, driven by a recognition of statin intolerance and the importance of cumulative LDL-C exposure. This represents a significant opportunity for Esperion, but also intensifies competition in a market already populated by established therapies and emerging PCSK9 inhibitors. The guidelines' emphasis on combination therapies could accelerate market evolution and necessitate strategic adjustments for all players.

What we're watching

Adoption Rate
The speed at which clinicians incorporate bempedoic acid into treatment plans will depend on physician education and patient acceptance, potentially impacting Esperion’s revenue projections.
Competitive Landscape
The guideline’s positioning of bempedoic acid relative to PCSK9 inhibitors and ezetimibe will shape market share dynamics and influence pricing strategies.
Combination Therapies
The potential for future approval of triple combination therapies (bempedoic acid, ezetimibe, and statin) could significantly expand the addressable market and create new competitive pressures.

Esperion Acquires Corstasis, Eyes Expansion into Rare Disease Markets

Event summary

  • Esperion reported FY25 revenue of $403.1 million, a 21% increase year-over-year, with U.S. net product revenue growing 38% to $159.6 million.
  • Q4 2025 revenue reached $168.4 million, a 144% increase year-over-year, and U.S. net product revenue was $43.7 million, up 38%.
  • Esperion has agreed to acquire Corstasis Therapeutics, gaining access to Enbumyst™ (bumetanide nasal spray), a treatment for edema associated with congestive heart failure.
  • The acquisition of Corstasis is estimated to target a $4 billion U.S. market opportunity for Enbumyst™.
  • Esperion expects full year 2026 operating expenses to be in the range of $225 million to $255 million.

The big picture

Esperion's acquisition of Corstasis represents a strategic pivot towards expanding its product portfolio beyond its core bempedoic acid franchise and into the larger, underserved market for edema treatment. This move, coupled with the ambitious 'Vision 2040' plan, signals an intent to transform Esperion into a more diversified, innovation-driven company, but also introduces integration and execution risks. The company's reliance on partnerships for global expansion highlights the complexities of navigating international markets in the pharmaceutical sector.

What we're watching

Integration Risk
The success of the Corstasis acquisition hinges on Esperion’s ability to effectively integrate the new business and leverage its commercial infrastructure, which could be complicated by differing operational cultures and sales strategies.
Patent Defense
While settlements have removed immediate generic challenges, the remaining patent litigation and impending expirations in 2036 and 2040 pose a long-term threat to Esperion’s revenue stream and necessitate continued investment in patent protection.
Pipeline Progress
The advancement of Esperion’s oral triple combination lipid-lowering program, targeting a 2027 commercialization date, will be critical to sustaining growth beyond existing products and competing with established therapies.

Esperion Acquires Corstasis, Bolsters Cardiovascular Portfolio with Nasal Diuretic

Event summary

  • Esperion Therapeutics has agreed to acquire Corstasis Therapeutics for $75 million upfront, with up to $180 million in potential milestone payments and royalties.
  • The acquisition centers on Enbumyst™, the first FDA-approved nasal spray loop diuretic for edema associated with congestive heart failure, approved in September 2025.
  • Esperion will finance the acquisition through existing credit facilities and royalty monetization.
  • The deal is expected to close in the second quarter of 2026.
  • Corstasis is also advancing a subcutaneous pipeline, including a multidose pen injector.

The big picture

Esperion's acquisition of Corstasis represents a strategic move to expand its cardiovascular franchise and capitalize on the unmet need for rapid-acting diuretics in managing edema associated with heart failure. The $4 billion market opportunity, coupled with Esperion’s existing commercial infrastructure, suggests a significant potential for revenue growth, but hinges on successful integration and regulatory expansion. This acquisition aligns with Esperion’s Vision 2040, signaling a broader commitment to innovation in cardiovascular care.

What we're watching

Commercial Execution
Esperion's ability to successfully integrate Enbumyst into its existing commercial infrastructure will be critical to realizing the anticipated revenue growth and justifying the acquisition cost.
Regulatory Expansion
The speed at which Esperion can expand Enbumyst’s indications beyond CHF, particularly into hepatic and renal disease, will influence its long-term market penetration.
Pipeline Progress
The development and potential commercialization of Corstasis’s subcutaneous pipeline, particularly the multidose pen injector, could unlock additional revenue streams beyond Enbumyst’s current scope.

Esperion to Detail 2025 Results Amid Pipeline Diversification

Event summary

  • Esperion Therapeutics will release its fourth quarter and full year 2025 financial results on March 10, 2026.
  • A webcast and replay will be available on the company's investor relations website starting at 8:00 a.m. ET.
  • Esperion markets two oral, once-daily, non-statin therapies for LDL-C management.
  • The company has global approvals in over 40 countries and a U.S. commercial infrastructure.
  • Esperion is expanding its pipeline to include treatments for Primary Sclerosing Cholangitis and renal diseases.

The big picture

Esperion's focus on ACLY biology and expansion beyond LDL-C therapies signals a strategic shift towards diversifying revenue streams and addressing unmet medical needs. The company's positioning as a partner for global innovators suggests a potential avenue for growth through in-licensing and co-promotion agreements, but this strategy's success hinges on attracting and retaining those partners. The upcoming earnings call will provide insight into the financial impact of these initiatives and the overall health of the business.

What we're watching

Pipeline Progress
The success of Esperion's pipeline expansion into areas like Primary Sclerosing Cholangitis and renal diseases will be crucial for long-term growth, potentially offsetting reliance on existing LDL-C therapies.
Commercial Execution
How Esperion leverages its U.S. commercial infrastructure and global approvals to drive revenue growth will be a key indicator of operational efficiency and market penetration.
Partner Strategy
The company's stated ambition to be a partner-of-choice for global innovators will require demonstrating a clear value proposition and successfully executing on acquisition or co-promotion deals.

Esperion Secures Key Patent Settlement, Extending Generic Exclusivity

Event summary

  • Esperion has reached a settlement agreement with Alkem Laboratories, preventing Alkem from marketing generic versions of NEXLETOL and NEXLIZET in the U.S. before April 19, 2040.
  • The settlement resolves patent litigation initiated by Esperion against Alkem.
  • Litigation against four other ANDA filers (Aurobindo, MSN Pharmaceuticals, Renata, and Sandoz) remains ongoing.
  • The agreement extends Esperion’s exclusivity period for its key cardiovascular therapies.

The big picture

This settlement significantly reduces near-term generic erosion risk for Esperion’s flagship products, NEXLETOL and NEXLIZET, which generate substantial revenue. While the agreement with Alkem is positive, the continued litigation highlights the ongoing challenges pharmaceutical companies face in protecting their intellectual property. The extended exclusivity period provides Esperion with more time to develop and commercialize its pipeline and potentially seek acquisition or partnership opportunities.

What we're watching

Litigation Risk
The ongoing patent litigation with Aurobindo, MSN Pharmaceuticals, Renata, and Sandoz will determine the ultimate scope of Esperion’s exclusivity and potential future generic competition.
Financial Impact
How the outcomes of the remaining patent challenges will affect Esperion’s revenue projections and valuation remains a key factor for investors.
Pipeline Progression
The company’s ability to advance its pipeline beyond NEXLETOL and NEXLIZET, particularly treatments for Primary Sclerosing Cholangitis and renal diseases, will be crucial to long-term growth.

Esperion to Present at J.P. Morgan Healthcare Conference

Event summary

  • Esperion will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2025.
  • The presentation and fireside chat will begin at 2:15 PM PT / 5:15 PM ET.
  • A webcast of the presentation will be available on Esperion’s website.
  • Esperion markets two oral, once-daily, non-statin therapies for cardiovascular disease.

The big picture

Esperion’s participation in J.P. Morgan’s Healthcare Conference signals an effort to bolster investor confidence and potentially attract partnerships. The company’s focus on ACLY biology and its commercial infrastructure positions it as a potential acquisition target or partner for larger pharmaceutical companies seeking U.S. market access, though the success of this strategy remains to be seen. The conference provides a platform to articulate this value proposition to a broad audience of institutional investors.

What we're watching

Pipeline Diversification
The conference presentation will likely highlight Esperion’s pipeline beyond its current marketed therapies, particularly its efforts in Primary Sclerosing Cholangitis and renal diseases, which will be scrutinized for potential revenue contribution.
Commercial Strategy
Esperion’s stated ambition to be a partner-of-choice for global innovators seeking U.S. market access will be tested by investor sentiment regarding the viability of this strategy and its impact on margins.
Global Reach
The company's global approvals across more than 40 countries suggest a broad international footprint; however, the sustainability of this expansion and its contribution to overall revenue will be a key area of investor focus.

Esperion Gains Ground as Bempedoic Acid Endorsed in Key PAD/Diabetes Guidelines

Event summary

  • Esperion’s bempedoic acid has been recommended as a first-line therapy for LDL-C lowering in patients with peripheral artery disease (PAD) and diabetes within the 2025 ACC Scientific Statement.
  • The recommendation highlights bempedoic acid’s proven cardiovascular and limb benefits, particularly for patients already taking maximally tolerated statins.
  • Data from the 2024 AHA Scientific Sessions, analyzing major adverse limb events (MALE) in the CLEAR Outcomes trial, showed a 36% reduction with bempedoic acid compared to placebo.
  • Esperion anticipates further endorsement of bempedoic acid in forthcoming U.S. dyslipidemia treatment guidelines from ACC/AHA in early 2026.

The big picture

This endorsement represents a significant validation of Esperion’s bempedoic acid, positioning it as a crucial therapy for a large and underserved patient population. The prevalence of diabetes and PAD creates a substantial market opportunity, but the success of bempedoic acid will depend on its ability to overcome existing treatment barriers and demonstrate sustained clinical benefit. The ACC’s recommendation provides a strong foundation for Esperion to expand its commercial footprint and potentially attract further investment.

What we're watching

Guideline Adoption
The speed with which clinicians incorporate the ACC’s recommendation into practice will be a key driver of bempedoic acid adoption and Esperion’s revenue growth.
Regulatory Landscape
The forthcoming ACC/AHA guidelines in early 2026 will be critical; a favorable inclusion could significantly expand bempedoic acid’s market reach.
Competitive Dynamics
How competitors respond to this endorsement, particularly in terms of pricing and marketing strategies, will shape the long-term competitive landscape for LDL-C lowering therapies.
CID: 540